Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT01132547) enrolled 22 people in total — 9 in the group receiving cyproheptadine hydrochloride (a medication) and 13 in the group receiving a placebo (a dummy treatment with no active ingredient). The trial was measuring changes in body weight over 8 weeks in participants who were losing weight, comparing those who received the medication against those who received the placebo. Not everyone finished the trial: 5 of the 9 people in the medication group completed it, compared with 12 of the 13 in the placebo group. The reported data shows two primary things were measured. First, the number of participants who lost 5% or more of their body weight by the 8-week mark: 0 out of 9 in the medication group and 2 out of 13 in the placebo group met this threshold. Second, the change in a weight "Z score" (a number that compares a person's weight to what is typical for their age and size) from the start to the end of the trial: the medication group's Z score increased by 0.12 on average, while the placebo group's Z score decreased by 0.02 on average. For the secondary outcome — actual change in body weight in kilograms — the reported data shows the medication group gained an average of 0.18 kg, while the placebo group lost an average of 0.32 kg. It is worth noting that this was a very small trial, with only 22 participants at the start and even fewer completing it, which means the numbers above reflect a limited group of people. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Peripheral Arterial Disease Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 2 and 21 years old when joining the study
- You are scheduled to receive chemotherapy for a newly diagnosed cancer, including certain soft tissue sarcomas, rhabdomyosarcoma, bone cancer (osteosarcoma), Ewing's sarcoma, neuroblastoma, Wilms' tumor (Stage III/IV), liver cancer (hepatoblastoma, Stage III/IV), germ cell tumors (Stage III/IV), certain brain tumors, or a blood cancer called AML
- You have a cancer that has come back or stopped responding to treatment (any type)
- You are able to join the study within 28 days of starting chemotherapy
Who may not be able to join:
- You started chemotherapy more than 28 days ago
- You have lost 5% or more of your body weight unintentionally in the last 3 months, thought to be related to cancer
- You are currently taking, or have taken in the last 3 weeks, a medication called cyproheptadine
- You have a history of eating disorders such as anorexia nervosa or bulimia
- You have taken appetite-stimulating medications such as dronabinol (Marinol) in the past 3 weeks
- You are taking or plan to take other medications or treatments to increase appetite or cause weight gain, including certain steroids or tube feeding
- You have been taking steroids as part of your cancer treatment for more than 7 days (short-term steroid use for nausea is allowed)
- You are taking certain medications including MAO inhibitors, procarbazine, fluoxetine (Prozac), or paroxetine (Paxil)
- You have been diagnosed with glaucoma, cystic fibrosis, inflammatory bowel disease, or a blockage in your digestive or urinary system
- You have a known allergy to cyproheptadine
- You are female and currently pregnant
- You are female and breastfeeding, unless you agree to stop breastfeeding during the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Participant With Weight Loss ≥ 5% at the 8- Week Assessment When Compared to Baseline; Severity of Weight Loss
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.